Redcliffe Life Sciences on Friday said it raised $61 million led by LeapFrog Investments. Other investors, including Healthquad, Schroders, LC Nueva, Growth Spark Ventures, and existing investors Chiratae Ventures and Alkemi Venture Partners, also participated in the round.
The platform will use the funds to expand its low-cost but high-quality direct-to-consumer diagnostics into Tier-II, III, and IV cities, which will provide affordable, rapid, and convenient pathology services in millions of households. This investment will help them scale rapidly to achieve their goal to reach 500 million+ Indians within the next five years.